Search

Your search keyword '"Cao Jingjing"' showing total 29 results
Start Over Author "Cao Jingjing" Publisher mdpi ag
29 results on '"Cao Jingjing"'

22. A H2O2-Responsive Boron Dipyrromethene-Based Photosensitizer for Imaging-Guided Photodynamic Therapy

Author

Xiao-Qiang Li, Zhi-Wei Wang, Cao Jingjing, Jian-Yong Liu, Su Dan, and De-Chao Yang

Subjects
medicine.medical_treatment, Pharmaceutical Science, Photodynamic therapy, 02 engineering and technology, 010402 general chemistry, Photochemistry, 01 natural sciences, Photoinduced electron transfer, Analytical Chemistry, HeLa, lcsh:QD241-441, chemistry.chemical_compound, lcsh:Organic chemistry, Drug Discovery, medicine, Photosensitizer, Physical and Theoretical Chemistry, activatable photosensitizers, photoinduced electron transfer (PET), biology, Singlet oxygen, Dimethyl sulfoxide, H2O2-responsive, Organic Chemistry, 021001 nanoscience & nanotechnology, biology.organism_classification, Fluorescence, 0104 chemical sciences, chemistry, photodynamic therapy, Chemistry (miscellaneous), Molecular Medicine, BODIPY, 0210 nano-technology
Abstract

In this study, we demonstrate a novel H2O2 activatable photosensitizer (compound 7) which contains a diiodo distyryl boron dipyrromethene (BODIPY) core and an arylboronate group that quenches the excited state of the BODIPY dye by photoinduced electron transfer (PET). The BODIPY-based photosensitizer is highly soluble and remains nonaggregated in dimethyl sulfoxide (DMSO) as shown by the intense and sharp Q-band absorption (707 nm). As expected, compound 7 exhibits negligible fluorescence emission and singlet oxygen generation efficiency. However, upon interaction with H2O2, both the fluorescence emission and singlet oxygen production of the photosensitizer can be restored in phosphate buffered saline (PBS) solution and PBS buffer solution containing 20% DMSO as a result of the cleavage of the arylboronate group. Due to the higher concentration of H2O2 in cancer cells, compound 7 even with low concentration is particularly sensitive to human cervical carcinoma (HeLa) cells (IC50 = 0.95 &mu, M) but hardly damage human embryonic lung fibroblast (HELF) cells. The results above suggest that this novel BODIPY derivative is a promising candidate for fluorescence imaging-guided photodynamic cancer therapy.

Published
2018

23. Evaluation of Small Molecule Combinations against Respiratory Syncytial Virus In Vitro

Author

Pan Xing, Ralf Altmeyer, Youming Zhang, Cao Jingjing, and Yuzhen Gao

Subjects
Cyclopamine, Combination therapy, Thiazepines, Pharmaceutical Science, Respiratory Syncytial Virus Infections, Drug resistance, Pharmacology, Antiviral Agents, Article, Virus, combination therapy, Analytical Chemistry, Small Molecule Libraries, synergistic enhancement, 03 medical and health sciences, chemistry.chemical_compound, QD241-441, Lower respiratory tract infection, Drug Discovery, medicine, Humans, Sulfones, Physical and Theoretical Chemistry, Pathogen, Viral Fusion Protein Inhibitors, 030304 developmental biology, 0303 health sciences, 030306 microbiology, business.industry, Organic Chemistry, RSV, fusion inhibitors, Drug Synergism, RNA-Dependent RNA Polymerase, medicine.disease, In vitro, chemistry, Chemistry (miscellaneous), Respiratory Syncytial Virus, Human, Quinazolines, Molecular Medicine, Drug Therapy, Combination, RdRp inhibitors, Antagonism, business
Abstract

Respiratory syncytial virus (RSV) is a major pathogen that causes severe lower respiratory tract infection in infants, the elderly and the immunocompromised worldwide. At present no approved specific drugs or vaccines are available to treat this pathogen. Recently, several promising candidates targeting RSV entry and multiplication steps are under investigation. However, it is possible to lead to drug resistance under the long-term treatment. Therapeutic combinations constitute an alternative to prevent resistance and reduce antiviral doses. Therefore, we tested in vitro two-drug combinations of fusion inhibitors (GS5806, Ziresovir and BMS433771) and RNA-dependent RNA polymerase complex (RdRp) inhibitors (ALS8176, RSV604, and Cyclopamine). The statistical program MacSynergy II was employed to determine synergism, additivity or antagonism between drugs. From the result, we found that combinations of ALS8176 and Ziresovir or GS5806 exhibit additive effects against RSV in vitro, with interaction volume of 50 µM2% and 31 µM2% at 95% confidence interval, respectively. On the other hand, all combinations between fusion inhibitors showed antagonistic effects against RSV in vitro, with volume of antagonism ranging from −50 µM2 % to −176 µM2 % at 95% confidence interval. Over all, our results suggest the potentially therapeutic combinations in combating RSV in vitro could be considered for further animal and clinical evaluations.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results